CCL2 and metabolic dysfunction-associated steatohepatitis: Drugs antagonizing CCL2 and CCL5 receptors to reduce macrophage recruitment to the liver have shown efficacy in reversing NASH phenotype in preclinical models and phase II clinical trials [52].